Graves’ Disease Clinical Trials Outlook 2026: Market Competition, Regulatory Progress, Emerging Therapies, Mechanisms, and Delivery Approaches – By DelveInsight

Graves’ Disease Clinical Trials Analysis

DelveInsight’s “Graves’ Disease Pipeline Insight, 2026” presents a detailed evaluation of the advancing treatment landscape for Graves’ Disease (GD). With over 10 emerging drug candidates progressing through clinical and preclinical stages and more than 8 prominent pharma and biotech companies developing next-generation therapies, the Graves’ Disease market is undergoing notable evolution.

The report delivers comprehensive intelligence on ongoing clinical trials, mechanisms of action, administration routes, therapeutic classifications, and collaborative research initiatives, offering valuable guidance for industry stakeholders, investors, and medical professionals.

Unlock detailed insights into the Graves’ Disease therapeutics by downloading the comprehensive report from DelveInsight @ Graves’ Disease Pipeline Outlook

Key Highlights from the Graves’ Disease Market Analysis

• According to DelveInsight’s assessments, Graves’ disease accounts for approximately 60–80% of hyperthyroidism cases. Although it is the leading cause, its overall prevalence remains relatively low, affecting nearly 1.2% of the US population.
• The American Thyroid Association (2024) reports that over 12% of Americans will experience a thyroid disorder during their lifetime, with nearly 20 million individuals currently living with thyroid disease. Women are five to eight times more likely than men to develop thyroid-related conditions.
• Data from the National Institute of Diabetes and Digestive and Kidney Diseases (2021) indicates that Graves’ disease impacts roughly 1 in 100 Americans.
• Research by Shang et al. (2024) estimates that 2.7–3.0% of China’s adult population—representing over 31 million people—suffers from autoimmune disorders, with autoimmune thyroid diseases and rheumatoid arthritis being the most prevalent contributors.
• Key companies active in the Graves’ Disease pipeline include Apitope International NV, Immunovant Sciences GmbH, Novartis Pharmaceuticals, Pfizer, Hoffmann-La Roche, and others.
• Prominent therapies under development include linsitinib, batoclimab, teprotumumab, VRDN-001 (10 mg/kg), satralizumab, IBI311, among others.

Recent Progress in the Graves’ Disease Pipeline

Over the past year, the Graves’ Disease and thyroid eye disease (TED) landscape has seen multiple significant milestones:

• February 2026 – Immunovant Sciences GmbH reported findings from its Phase 2b randomized, double-blind, placebo-controlled study evaluating IMVT-1402 in adults with Graves’ Disease.
• January 2026 – Merida Biosciences announced Phase 1 results assessing safety, pharmacokinetics, pharmacodynamics, and immunogenicity of MER511 administered intravenously and subcutaneously in GD patients.
• December 2025 – Sanofi disclosed outcomes from a Phase 2 open-label study investigating rilzabrutinib in adult GD patients.
• September 2025 – Immunovant, Inc. presented six-month off-treatment data on batoclimab at the Annual Meeting of the American Thyroid Association (ATA).
• May 2025 – Amgen secured UK MHRA approval for TEPEZZA® (teprotumumab) for moderate-to-severe TED, marking the first authorized therapy in the UK for adult TED patients.
• May 2025 – Viridian Therapeutics Inc. obtained FDA Breakthrough Therapy Designation for veligrotug (veli), targeting IGF-1R in TED.
• January 2025 – Sling Therapeutics shared Phase 2b/3 LIDS trial topline results for linsitinib, an oral IGF-1R inhibitor.
• December 2024 – Viridian Therapeutics Inc. reported favorable Phase 3 THRIVE-2 trial data for veligrotug in chronic TED.

These advancements underscore the intensifying research focus on thyroid-associated ophthalmopathy and demonstrate the pipeline’s expansion beyond conventional GD treatments.

Gain a competitive edge in the Graves’ Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Graves’ Disease Treatment Drugs

Graves’ Disease Competitive Landscape Overview

Numerous pharmaceutical and biotechnology firms are actively striving to bridge therapeutic gaps in Graves’ Disease management. DelveInsight identifies the following key contributors to the Graves’ Disease pipeline:

• TSHR Septerna
• advanceCOR
• EVOQ Therapeutics
• Worg Pharmaceuticals
• AV7 Limited
• Novartis Pharmaceuticals
• Immunovant Sciences GmbH
• And several others

These companies are pursuing diverse mechanisms including TSH receptor modulation, IGF-1R inhibition, monoclonal antibody development, and innovative small-molecule strategies.

Promising Graves’ Disease Candidates in Development

The Graves’ Disease pipeline spans early research to late-stage clinical programs. Noteworthy candidates include:

• TSHR Septerna’s receptor-modulating research initiative
• advanceCOR’s peptide-based therapeutic program
• EVOQ Therapeutics’ nanotechnology-focused platform
• WP-1302 by Worg Pharmaceuticals (early clinical development)
• K1-70 by AV7 Limited (TSH receptor monoclonal antibody)
• CFZ533 by Novartis Pharmaceuticals (immunomodulatory therapy)
• Batoclimab by Immunovant Sciences GmbH, an FcRn inhibitor targeting autoimmune thyroid disorders

These emerging options hold promise for patients who exhibit limited response to current standards of care.

Download DelveInsight’s Graves’ Disease Market report today and stay ahead in this rapidly evolving field. @ Graves’ Disease Clinical Trials and FDA Approvals

Graves’ Disease Overview

Graves’ Disease represents the most prevalent cause of hyperthyroidism worldwide. It is an autoimmune condition in which antibodies stimulate the thyroid gland to produce excess hormones. Clinical manifestations include weight loss, tachycardia, anxiety, tremors, goiter, and thyroid eye disease (TED).

Diagnosis typically involves thyroid function testing, thyroid-stimulating immunoglobulin measurement, and imaging procedures such as radioactive iodine uptake scans.

Conventional management approaches include antithyroid medications (methimazole, propylthiouracil), radioactive iodine therapy, and surgical thyroidectomy. However, relapse risk, adverse events, and long-term complications continue to drive demand for biologics, monoclonal antibodies, and targeted therapies.

Graves’ Disease Pipeline by Route of Administration

Investigational therapies are being formulated across various delivery methods to enhance convenience and clinical outcomes:

• Oral
• Parenteral
• Intravenous (IV)
• Subcutaneous (SC)
• Topical

Graves’ Disease Molecule Class Distribution

Graves’ Disease Pipeline therapies encompass a broad spectrum of molecular categories:

• Monoclonal antibodies
• Peptide-based therapeutics
• Polymer-based agents
• Small molecules
• Gene therapy approaches

This diversity highlights the industry’s comprehensive strategy to address multiple immunological pathways involved in GD.

Discover key developments and opportunities in the Graves’ Disease Market. Click here to learn more from DelveInsight’s latest report @ Graves’ Disease Market Dynamics

Graves’ Disease Market Dynamics: Drivers and Challenges

Graves’ Disease Growth Drivers

• Increasing global incidence of Graves’ Disease
• Improved awareness and early diagnostic rates
• Expanding R&D investments across pharma and biotech
• Accelerated regulatory pathways and breakthrough designations

Graves’ Disease Market Barriers

• Elevated costs associated with biologics and advanced antibody therapies
• Risks and complications linked to traditional treatment modalities
• Limited accessibility of innovative therapies in emerging economies

Scope of the Graves’ Disease Market Report

• Geographic Coverage: 7MM
• Key Companies: Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals (SWX: NOVN), AV7 Limited, Medtronic (NYSE: MDT), Pfizer (NYSE: PFE), Sanguine Biosciences, Tourmaline Bio Inc. (NASDAQ: TRML), Horizon Pharma USA Inc., Viridian Therapeutics Inc. (NASDAQ: VRDN), Innovent Biologics Co. Ltd (HKEX: 1801), Hoffmann-La Roche (SWX: RO), and others.
• Key Therapies: linsitinib, batoclimab, teprotumumab, VRDN-001, satralizumab, IBI311, among others.
• Competitive Intelligence: SWOT analysis and entry strategies
• Unmet needs, KOL insights, analyst perspectives, and reimbursement landscape

Download the report to understand which factors are driving Graves’ Disease Market Dynamics @ Graves’ Disease Market Trends

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/partner-identification-services